Overview

Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Dexlansoprazole
Esomeprazole
Lansoprazole